---
title: Pfizer (PFE) — intrinsic value and fair price
canonical: https://sweetvaluelab.com/stocks/pfe
ticker: PFE
as_of: 2026-10-17
sector: Healthcare
industry: Drug Manufacturers - General
---
# Pfizer (PFE)

Pfizer (PFE) closed at $29.58 on Oct 16, 2026, undervalued by 3% vs its model value of $30.39 (from a five-year discounted cash flow).

## Key figures

| Figure | Value |
| --- | ---: |
| Last close | $29.58 (Oct 16, 2026) |
| Model value (from a five-year discounted cash flow) | $30.39 |
| Price vs model | undervalued by 3% vs model |
| Range of that model | $12.41 – $64.63 |
| Market value | $168.6B |
| P/E (fiscal 2025) | 21.7 |
| Net margin (fiscal 2025) | 12.4% |
| Free cash flow (fiscal 2025) | $9.1B |
| Dividend yield (trailing twelve months) | 5.81% |
| Beta | 0.28 |
| Cost of capital (WACC) | 6.33% |
| Business classification | Mature & Stable (Moderate growth (~11% recent), Moderate margins (12% net margin), Highly cyclical earnings, Strong FCF yield (5.4%)) |

## On the stock lists

| List | Place | Figure | Page |
| --- | ---: | ---: | --- |
| Highest dividend yield | #13 | 5.81% | https://sweetvaluelab.com/lists/highest-dividend-yield |
| Near 52-week highs | #21 | 0.0% | https://sweetvaluelab.com/lists/near-52-week-highs |
| Insider buying | #11 | $3.0M | https://sweetvaluelab.com/lists/insider-buying |

## Dividends

| Figure | Value |
| --- | ---: |
| Trailing dividend yield | 5.81% |
| Dividends per share, last 12 months | $1.72 |
| Coverage | — |
| Raised | 16 years in a row |
| Growth over 5 years | 2.1% a year |
| Latest payment | $0.43, ex-date Jul 24, 2026, paid Sep 1, 2026 |

| Year of payments | Dividends per share |
| --- | ---: |
| To Jul 29, 2021 | $1.55 |
| To Jul 28, 2022 | $1.59 |
| To Jul 27, 2023 | $1.63 |
| To Jul 26, 2024 | $1.67 |
| To Jul 25, 2025 | $1.71 |
| Trailing twelve months (to Jul 24, 2026) | $1.72 |

## Valuation models

Each model's value per share and the role the engine gave it for this business. The headline above is one model's value; every other model is listed with its own, and each has a page of its own under the valuation. Computed Oct 17, 2026.

| Model | Role | Value per share | Low | High |
| --- | --- | ---: | ---: | ---: |
| DCF · Perpetuity growth · 5y | primary | $30.39 | $12.41 | $64.63 |
| DCF · Perpetuity growth · 10y | cross check | $26.42 | $11.33 | $57.61 |
| DCF · EBITDA exit · 5y | cross check | $19.25 | $11.51 | $28.38 |
| DCF · EBITDA exit · 10y | cross check | $18.31 | $10.81 | $28.30 |
| P/E · peers | cross check | $46.06 | $25.75 | $51.90 |
| P/E · own history | cross check | $38.12 | $26.84 | $45.43 |
| PEG | sanity check | $36.86 | $36.86 | $36.86 |
| EV/EBITDA · peers | cross check | $33.85 | $25.47 | $45.70 |
| EV/Revenue · peers | cross check | $56.79 | $41.60 | $74.33 |
| Earnings power value | cross check | $24.46 | $17.64 | $35.51 |
| Dividend discount | cross check | $36.62 | $24.97 | $76.10 |

## Insider activity (SEC Form 4)

Past 90 days: 3 open-market buys ($3.0M) and 1 open-market sale ($83,261.2); 10b5-1 plan sales included.

| Date | Insider | Relationship | Transaction | Shares | Value |
| --- | --- | --- | --- | ---: | ---: |
| Oct 15, 2026 | BOURLA ALBERT | Chairman & CEO | Grant / award | 20 | $588.8 |
| Oct 13, 2026 | BOURLA ALBERT | Chairman & CEO | Grant / award | 71 | $2,014.3 |
| Sep 30, 2026 | BOURLA ALBERT | Chairman & CEO | Grant / award | 21 | $598.9 |
| Sep 25, 2026 | Buckley Mortimer J | Director | Grant / award | 1,307.987 | $37,500 |
| Sep 25, 2026 | Echevarria Joseph | Director | Grant / award | 1,613.185 | $46,250 |

## Recent SEC filings

| Filed | Form | What | Filing |
| --- | --- | --- | --- |
| Aug 4, 2026 | 10-Q | Quarterly report | https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm |
| Aug 4, 2026 | 8-K | 2.02 Results of Operations (Earnings); 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/78003/000007800326000094/pfe-20260804.htm |
| Jun 18, 2026 | 8-K | 7.01 Regulation FD Disclosure | https://www.sec.gov/Archives/edgar/data/78003/000007800326000087/pfe-20260618.htm |
| Jun 18, 2026 | 8-K | 5.02 Departure/Election of Directors or Officers; 9.01 Financial Statements and Exhibits | https://www.sec.gov/Archives/edgar/data/78003/000007800326000085/pfe-20260618.htm |
| May 5, 2026 | S-8 | Employee stock plan registration | https://www.sec.gov/Archives/edgar/data/78003/000007800326000058/forms-82019planamended2026.htm |

## Superinvestors holding it (latest 13F)

| Manager | Quarter | Shares | Value |
| --- | --- | ---: | ---: |
| Richard Pzena | 2026-06-30 | 5,958,922 | $143.5M |
| Harry Burn | 2026-06-30 | 3,820,117 | $92.0M |
| Sarah Ketterer | 2026-06-30 | 1,916,801 | $46.2M |
| Prem Watsa | 2026-06-30 | 1,043,900 | $25.1M |

11 tracked managers in all.

## About

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar fa…

---

Source: https://sweetvaluelab.com/stocks/pfe (SweetValueLab, free, no account). Prices and statements from Financial Modeling Prep; filings from SEC EDGAR. Research and educational data, not investment advice; nothing here is a recommendation to buy, sell or hold any security.